News

Take-Two Interactive Votes on Leadership and Future Projects

Take-Two Interactive Votes on Leadership and Future Projects

Take-Two Interactive Shareholders Confirm Leadership

During a recent virtual annual meeting, shareholders of Take-Two Interactive Software Inc. (NASDAQ: TTWO) came together to discuss key proposals that will influence the company’s future direction. This year’s meeting had a strong turnout, with over 156 million shares represented, showing just how engaged the shareholders are.

Board Members Re-elected for New Terms

At the meeting, shareholders overwhelmingly voted to re-elect all nominated directors to continue serving on the board until the next annual meeting in 2025. Key figures like Strauss Zelnick, William "Bing" Gordon, and Ellen Siminoff will keep their positions, with approval ranging from 131 million to 145 million votes in favor. This strong consensus is a clear sign of trust in the company’s leadership at a critical time for the gaming industry.

Executive Compensation Approved

Shareholders took the opportunity to approve the compensation packages for the named executive officers. The proposal received over 125 million votes of support, compared to around 20 million against it, along with approximately 291,000 abstentions. This backing underscores the confidence investors place in the leadership team's capability to guide the company toward growth.

Independent Auditor Appointment Ratified

Another important decision made during the meeting was the ratification of Ernst & Young LLP as the independent auditors for Take-Two for the fiscal year ending March 31, 2025. With more than 153 million votes in favor, this action highlights a commitment to transparency and strong financial practices.

Exciting Developments on the Horizon

Take-Two Interactive is buzzing with anticipation for several exciting developments. The company has teamed up with W?t? Workshop to launch "Tales of the Shire: A The Lord of The Rings Game," which is scheduled for release in March 2025, drawing in fans of this cherished franchise. Additionally, a legal challenge is on the horizon as Take-Two confronts a $44.9 million patent infringement verdict tied to its subsidiary, Zynga Inc. (NASDAQ: ZNGA), which they plan to fight.

New Game Releases and Technological Innovations

Recently, Take-Two unveiled NBA 2K25, which features new ProPLAY technology to elevate the gaming experience. The company has also shared an exciting release schedule, featuring beloved franchises like "Borderlands 4" and "Mafia: The Old Country," both on track for 2025, along with "Sid Meier's Civilization VII," which is set for an early 2025 launch. These announcements reflect the company’s commitment to delivering top-notch gaming experiences to its players.

Analyst Insights and Market Position

Analysts from various financial firms are optimistic about Take-Two’s stock, maintaining "Buy" ratings. Stifel recently updated its non-GAAP EPS forecast for the fiscal year 2026 to $7.82, based on projected net bookings of $8.381 billion. The anticipated release of Grand Theft Auto VI is expected to play a significant role in boosting the company’s overall financial success, as it has consistently been one of the gaming industry’s top performers.

Impact of Ongoing Industry Strikes

Even with some disruptions in the industry caused by a recent strike involving voice actors and motion-capture artists represented by SAG-AFTRA, analysts from Wedbush Securities believe that the impact on Take-Two will be minimal. This is mainly because of the company’s strong in-house development teams and the lengthy development cycles for major game titles, which help them effectively navigate these challenges.

Frequently Asked Questions

What proposals were discussed at the Take-Two Interactive meeting?

Shareholders discussed the election of directors, executive compensation, and the appointment of independent auditors.

Who were the re-elected directors at the meeting?

Re-elected directors included Strauss Zelnick, William "Bing" Gordon, and Ellen Siminoff, among others.

What game is Take-Two set to release in early 2025?

Take-Two is gearing up to launch "Sid Meier's Civilization VII" in early 2025.

How have analysts rated Take-Two's stock?

Analysts have maintained "Buy" ratings for Take-Two, expecting solid earnings growth due to upcoming game releases.

What recent legal issue is Take-Two facing?

Take-Two is contending with a $44.9 million patent infringement verdict related to its subsidiary Zynga, which the company plans to appeal.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Innovent's Seven Drugs Leap onto 2026 Reimbursement Chart

Updated Category News Views 223

A Bold Move in Biopharmaceuticals Innovent Biologics just pulled a rabbit out of their hat. Seven of their cutting-edge meds made it onto China's National Reimbursement Drug List for 2026. This isn't just a spreadsheet entry—it's a lifeline thrown to patients across the oncology, metabolic, and autoimmune landscapes, as well as a financial booster for Innovent (HKEX:...

Continue Reading
CARsgen's CAR-T Breakthrough on China's Insurance List

Updated Category News Views 154

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

Continue Reading
Fluence Energy Faces Leadership Departures Amid Legal Woes

Updated Category News Views 122

Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....

Continue Reading
ManuTech Center Set to Revolutionize Manufacturing Hub

Updated Category News Views 207

Jackson's Next Manufacturing Frontier Well, the folks down in Jackson, Michigan, are prepping to cut the red ribbon on something that's got me leaning forward in my seat. The Advanced Manufacturing Training Center (AMTC) is pulling out all the stops with their new ManuTech Prototyping Center. Yup, this center is about to become the playground for startups, manufacturers,...

Continue Reading
Uber Data Breach: Class Action Investigation Begins

Updated Category News Views 22

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Continue Reading
SmallRig Boosts Art-Driven Innovation in AI Era

Updated Category News Views 148

The Interplay of Art and AI In a world where the lines between man and machine blur faster than ever, creators like SmallRig are boldly asking: what role should authenticity play when AI takes the stage? The Shenzhen International Art Museum and SmallRig stood shoulder to shoulder, tackling this head-scrambling question with a global gathering of art and tech giants. It's...

Continue Reading
WeFetch AI: A New Era in Barcode Precision

Updated Category News Views 225

WeFetch AI: What's in a Name? Forget about GreenCore Solutions Corp. We're talking about WeFetch AI Corp. now. They've just changed their name, fulfilling a bureaucratic tick as of November 13, 2026. But it ain't just a name change; it's a whole new ballgame in AI-driven commerce. AI Shopping Without the Guesswork We've all been there. You think you've ordered that...

Continue Reading
Servier's Data on Tovorafenib Shows Promise in pLGG

Updated Category News Views 155

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Continue Reading
EFICYENT Ventures to Connect at Singapore FinTech Fest

Updated Category News Views 150

Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...

Continue Reading
Gaine Expands Healthcare Data Solutions Ahead of HLTH 2026

Updated Category News Views 233

Ever felt like healthcare systems are still stuck in a bygone era, struggling with data flinging through the void? Well, Gaine Technology is throwing down its gauntlet to change that narrative. Successful in pharmaceuticals and life sciences, they're turbocharging their Consent and Preference Management solution across the vast, tangled web of healthcare markets just in...

Continue Reading
les" class="btn" href="https://investorshangout.com/blog/news?page=2">More News Articles